MEDICAMEN BIOTECH LIMITED (MEDICAMEQ)

NSE: ₹255.70
BSE: ₹255.50
Stock Performance
Corporate Announcements
Corporate Action-Board to consider Dividend

The Board of Directors of the comoany at the meeting held on Wednesday, May 27, 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each for the financial year ended March 31, 2026 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.

2026-05-28 12:21:43
2026-05-28 12:13:32
Announcement under Regulation 30 (LODR)-Newspaper Publication

Announcement under Regulation 30 (LODR) - Newspaper Publication for BM held on 27.05.2026

2026-05-28 11:52:55
Audited Stabdalone & Consolidated Financial Results For The Quarter And Year Ended On March 31, 2026

Audited Standalone & Consolidated Financial Results for the quarter and year ended on March 31, 2026

2026-05-27 15:26:09
Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated ) For The Quarter And Year Ended On March 31, 2026

the audited financial results (Standalone and Consolidated) for the quarter and year ended on March 31, 2026 and for recommendation of Final Divided for FY 2025-26 on Equity Shares of the Company.

2026-05-20 15:59:01
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Compliance Certifcate under Reg 74 (5) of SEBI (DP) Regulation , 2018

2026-04-16 16:36:22
2026-04-06 16:21:06
Closure of Trading Window

Intimation of Closure of Trading Window - March 2026

2026-03-30 12:52:08
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015

The company has on 27.01.2026 received a cautionery letter (Email) from NSE for observations reported by the Secretarial Auditor in ASCR for FY ended 31.03.2025.

2026-02-21 16:47:58
Announcement under Regulation 30 (LODR)-Change in Management

Corrigendum- Intimation regarding completion of term of Independent Directorship of Mr Harish Pande and Mr Arun Kumar

2026-02-18 18:01:03

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 41.94 43.54 46.50 47.32 43.05 44.74 45.14 29.61 43.04 47.17 46.91 60.65
YOY Revenue Growth % 26.76% 29.85% 30.69% 22.38% 2.64% 2.76% -2.92% -37.42% -0.01% 5.42% 3.91% 104.8%
Other Income 0.38 0.55 0.83 0.57 0.59 0.29 0.14 5.23 0.47 0.37 0.53 1.74
Total Income 42.32 44.09 47.33 47.89 43.63 45.03 45.28 34.84 43.52 47.54 47.44 62.38
Total Expenses + 37.64 41.63 44.06 45.23 42.08 43.08 41.41 32.35 41.38 44.86 45.33 57.32
Cost of Materials Consumed 26.11 27.67 29.10 21.82 21.67 28.94 28.52 11.52 24.60 21.97 21.69 26.09
Employee Benefit Expense 6.56 7.10 8.01 8.39 7.84 7.63 8.00 8.40 8.09 8.83 8.37 9.40
Other Expenses 7.56 8.65 8.62 9.58 7.68 7.35 8.11 9.06 7.63 10.03 10.45 13.61
Operating Profit 4.30 1.91 2.44 2.09 0.97 1.67 3.74 -2.74 1.66 2.31 1.58 3.32
OPM % 10.3% 4.4% 5.3% 4.4% 2.3% 3.7% 8.3% -9.2% 3.9% 4.9% 3.4% 5.5%
Profit Before Tax + 4.68 2.46 3.27 2.66 1.56 1.96 3.88 2.49 2.13 2.68 2.11 5.06
Tax Expense 0.74 0.99 1.24 0.62 0.76 1.05 0.95 0.63 0.53 0.57 0.48 0.61
Tax % 15.7% 40.1% 38% 23.2% 48.7% 53.8% 24.6% 25.2% 24.9% 21.2% 22.6% 12.1%
Profit After Tax 3.95 1.48 2.03 2.04 0.80 0.90 2.92 1.86 1.60 2.11 1.63 4.45
EPS (Basic) 3.12 1.17 1.60 1.61 0.63 0.71 2.30 1.47 1.18 1.56 1.21 3.28

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Revenue from Operations 197.77 162.55 179.31 140.87 115.45 112.72
YOY Revenue Growth % 21.67% -9.35% 27.29% 22.02% 2.42% -
Other Income 3.11 6.24 2.33 2.46 1.72 0.75
Total Income 200.88 168.79 181.63 143.33 117.17 113.47
Total Expenses + 188.90 158.91 168.56 126.28 99.07 97.08
Cost of Materials Consumed 94.35 90.65 104.70 81.80 55.69 68.42
Employee Benefit Expense 34.69 31.87 30.07 20.44 14.50 9.00
Other Expenses 41.72 32.20 34.40 24.46 25.04 15.03
Operating Profit 8.87 3.64 10.75 14.58 16.37 15.64
OPM % 4.5% 2.2% 6% 10.4% 14.2% 13.9%
Profit Before Exceptional 11.98 9.88 13.08 17.05 18.09 16.39
Exceptional Items 0.00 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 11.98 9.88 13.08 17.05 18.09 16.39
Tax Expense 2.19 3.32 3.58 2.32 3.20 4.26
Tax % 18.3% 33.6% 27.4% 13.6% 17.7% 26%
Profit After Tax 9.80 6.56 9.49 14.73 14.90 12.13
EPS (Basic) 7.22 5.16 7.50 11.82 12.19 9.93

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
ASSETS
Non-Current Assets + 148.25 132.33 134.93 115.15 102.66 97.97
Property, Plant & Equipment 84.09 86.12 90.95 91.76 92.12 89.43
Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 0.00
Non-Current Investments 0.00 0.00 0.00 0.00 0.00 0.00
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.57 0.74 0.90 0.90 0.36 0.20
Current Assets + 223.73 164.55 159.59 163.36 123.04 96.03
Inventories 70.08 62.14 59.38 45.06 27.01 5.20
Trade Receivables 81.83 68.90 55.26 65.26 63.22 3.89
Cash and Cash Equivalents 31.26 3.76 14.79 20.78 0.00 7.14
Current Investments 0.00 0.00 0.00 0.00 0.00 52.55
LIABILITIES & EQUITY
Total Equity 275.55 212.78 200.49 193.41 146.47 132.89
Equity Share Capital 13.56 12.71 12.71 12.65 12.22 12.22
Other Equity 261.99 200.07 187.77 180.76 134.25 120.67
Non-Current Liabilities 8.52 5.94 3.01 2.53 6.53 7.84
Current Liabilities 87.92 78.17 91.03 82.57 72.69 53.27
Total Liabilities 96.44 84.10 94.04 85.10 79.22 61.12

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Cash from Operating Activities -33.17 -7.19 -0.37 -6.29 4.11 12.77
Cash from Investing Activities -3.04 -1.89 -5.56 -5.88 -8.47 -17.81
Cash from Financing Activities 63.72 -1.94 -0.06 29.13 4.30 5.84
Net Increase/Decrease in Cash 27.50 -11.02 -5.99 16.95 -0.07 0.80